Figure 1.

NHANES 2013–2018 participants included in simulation modeling.

*ADA criteria for SGLT2I or GLP1RA use include adults with current atherosclerotic cardiovascular disease (ASCVD), who are at high risk for developing ASCVD, or who have heart failure or chronic kidney disease (CKD) to be placed on either a SGLT2I or GLP1RA. ADA, American Diabetes Association; GLP1RA, glucagon-like peptide-1 receptor agonist; NHANES, National Health and Nutrition Examination Survey; SGLT2I, sodium-glucose cotransporter-2 inhibitor.